血红蛋白病诊断实践跨国调查:HELIOS COST行动研究
结果显示血液学仍是诊断基石,DNA检测广泛采用但先进基因组学有限,新生儿筛查广泛覆盖镰状细胞病和地中海贫血,携带者报告实践各异,遗传修饰基因检测正在兴起。研究识别了可受益于共享 expertise 与资源的中心,为协调协议和强化诊断能力提供依据。
要点
- 血液学检查仍是血红蛋白病诊断的核心支柱。
- DNA检测广泛采用,但先进基因组学应用有限。
- 新生儿筛查广泛覆盖镰状细胞病和地中海贫血,携带者报告实践因国而异。
核心结论
- 跨国调查揭示血红蛋白病诊断实践存在差异,需协调协议并强化诊断能力。
主要发现
- 血液学为诊断骨干,DNA检测广泛采用而先进基因组学有限。
- 新生儿筛查广泛用于镰状细胞病和地中海贫血,携带者报告实践各异。
- 遗传修饰基因检测正在兴起。
临床怎么用
- 可依据调查识别需共享 expertise 与资源的中心,推动协议协调和最佳实践推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemoglobinopathies comprise the most common monogenic diseases worldwide. In Europe, formerly low-prevalence regions have seen increasing numbers of carriers and patients, with important public health implications. Implementation of policies and laboratory methodologies varies across countries, affecting equitable care. This study aimed to provide a snapshot of current screening and diagnostic practices and to identify gaps and priorities. A cross-sectional online survey was conducted from May to October 2024 across the COST (European Cooperation in Science and Technology) Action Haemoglobinopathies in European Liaison of Medicine and Science network participants. The survey, including 21 questions, covered hematological methods, molecular diagnostics, and laboratory practices and policies. Responses were provided directly by centers and summarized descriptively in tables and maps. Responses were received from 38 centers in 20 countries. Hematology remains the diagnostic backbone for hemoglobinopathies, DNA-based testing is widely adopted although advanced genomics are limited, newborn screening is implemented widely for sickle cell disease and thalassemia, carrier reporting practices vary, and genetic modifier testing is emerging. The findings highlight opportunities for cross-country collaboration and targeted capacity building, identifying centers that could benefit from shared expertise and resources. These findings can guide strategies to harmonize protocols, strengthen diagnostic capabilities, and support broader implementation of best practices across Europe.
引用
- Stephanou C, Chatzimatthaiou S, Kountouris P, et al. Mapping diagnostic practices in hemoglobinopathies: a cross-country HELIOS COST Action study. Blood Adv. 2026. PMID: 41610330. doi:10.1182/bloodadvances.2025019061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。